🟢 Synergistic Metabolic Targeting

Concept 1

A moderate hit on lactate production (Shikonin) + a moderate hit on lactate export (Silibinin + Naringenin) & a TME buffer (Bicarbonate). Individually, each has a limited effect. But together, they may synergize to create a targeted metabolic anticancer effect.

Click to expand the flowchart

Concept 2

Expanding on Concept 1; adding Glyoxalase I (GLO1) inhibition.

Cancer cells, which rely on high glycolysis, produce excess methylglyoxal (MG) and consequently overexpress GLO1 to survive. Inhibition of glycolysis (e.g., using Shikonin) generates an additional burden of toxic MG as a byproduct (mostly as a secondary effect resulting from the build-up of glycolytic intermediates that serve as MG precursors). By targeting GLO1 (e.g., piceatannol, myricetin, scutellarein), the cancer cell's primary and most crucial detoxification pathway for methylglyoxal is impaired, poisoning the cancer cell, leading to apoptosis. Note that healthy cells maintain a normal metabolic rate and primarily rely on oxidative phosphorylation for energy, resulting in low MG production, hence the potential for selective toxicity.

Click to expand the flowchart

Concept 3

Builds on concept 2 + methionine restriction.

Methionine restriction leverages a unique metabolic vulnerability of many cancer cells, often referred to as the Hoffman Effect.

Click to expand flowchart

While methionine restriction is a potent anti-tumor strategy, its effects are not universally beneficial and can be context-dependent. The most significant caveat is the dual role of methionine itself. While cancer cells exhibit an increased dependence on exogenous methionine, the amino acid is also needed for healthy immune cells, particularly T cells. So, a potential conflict arises because the same intervention that starves the tumor may possibly harm the host's anti-tumor immune response. One solution to this could be to use methionine restriction intermittently (e.g., a few days of restriction followed by a period of normal diet). A cyclical approach aims to provide the potent anti-tumor effects of methionine restriction while avoiding long-term, systemic immune suppression. It enables the body's immune system to remain part of the anti-tumor strategy, especially when combined with other immune-enhancing elements of the model.

Concept 4

Adding to concept 3, addressing metabolic plasticity and inverted pH: adding Glutamine & Ammonia scavenging (Phenylbutyrate/Rifaximin/etc)

Click to expand

Concept 5

+ Angiogenesis inhibition: theobromine (based on concept1 for clarity)

Click to expand

Concept 6

+ bicarbonate/arginine deprivation/cytotoxicity

Cancer cells can react to phenylbutyrate-induced nitrogen scarcity by upregulating the urea cycle to conserve nitrogen albeit at great expense of ATP expenditure. Arginine deprivation exploits this escape route. Alfalfa contains canavanine, a natural arginine analog. Cells with a high demand for arginine (like metabolically stressed cancer cells) will mistakenly import canavanine and incorporate it into proteins during synthesis. But because canavanine has a slightly different structure, it causes misfolding and dysfunction of these proteins.

Oral bicarbonate (sodium or potassium bicarbonate) is a simple, well-studied (in pre-clinical models) method to buffer and alkalize the tumor microenvironment. Cancer cells expend immense energy to maintain a reverse pH gradient (acidic outside, neutral/alkaline inside). This gradient is crucial for driving nutrient uptake and resisting apoptosis. Bicarbonate disrupts this gradient, adding to the energy crisis already induced by phenylbutyrate and arginine deprivation.

Click to expand the flowchart

References

Shi S, Li JC, Zhou XY, Li ZL, Wang YX, Xu BH, Ye S. Transport mechanism and drug discovery of human monocarboxylate transporter 1. Acta Pharmacol Sin. 2025 Aug;46(8):2323-2333. doi: 10.1038/s41401-025-01517-7. Epub 2025 Mar 17. PMID: 40097709; PMCID: PMC12274375.

Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, Damaghi M, Wojtkowiak JW, Mulé JJ, Ibrahim-Hashim A, Gillies RJ. Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. Cancer Res. 2016 Mar 15;76(6):1381-90. doi: 10.1158/0008-5472.CAN-15-1743. Epub 2015 Dec 30. Erratum in: Cancer Res. 2017 May 1;77(9):2552. doi: 10.1158/0008-5472.CAN-17-0559. PMID: 26719539; PMCID: PMC4829106.

Rahman MA, Yadab MK, Ali MM. Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy. Cells. 2024 Nov 20;13(22):1924. doi: 10.3390/cells13221924. PMID: 39594672; PMCID: PMC11592846.

Zhang Q, Liu Q, Zheng S, Liu T, Yang L, Han X, Lu X. Shikonin Inhibits Tumor Growth of ESCC by suppressing PKM2 mediated Aerobic Glycolysis and STAT3 Phosphorylation. J Cancer. 2021 Jun 11;12(16):4830-4840. doi: 10.7150/jca.58494. PMID: 34234853; PMCID: PMC8247391.

Gu XY, Yang JL, Lai R, Zhou ZJ, Tang D, Hu L, Zhao LJ. Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives. Front Immunol. 2025 Mar 26;16:1563303. doi: 10.3389/fimmu.2025.1563303. PMID: 40207222; PMCID: PMC11979165.

Rahman A, Janic B, Rahman T, Singh H, Ali H, Rattan R, Kazi M, Ali MM. Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model. Cancers (Basel). 2023 Oct 11;15(20):4931. doi: 10.3390/cancers15204931. PMID: 37894298; PMCID: PMC10605606.

Inoue M, Nakagawa Y, Azuma M, Akahane H, Chimori R, Mano Y, Takasawa R. The PKM2 inhibitor shikonin enhances piceatannol-induced apoptosis of glyoxalase I-dependent cancer cells. Genes Cells. 2024 Jan;29(1):52-62. doi: 10.1111/gtc.13084. Epub 2023 Nov 14. PMID: 37963646; PMCID: PMC11448369. **This finding is, in fact, proof of concept2, confirming that targeting both glycolysis and the glyoxalase system concurrently results in metabolic poisoning of the cancer cell, leading to apoptosis **

He, Yujiao & Zhou, Chunyan & Huang, Maolin & Tang, Chunyan & Liu, Xiao & Yue, Yan & Diao, Qingchun & Zheng, Zhebin & Liu, Deming. (2020). Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators. Biomedicine & Pharmacotherapy. 131. 110663. 10.1016/j.biopha.2020.110663.

Al-Balas, Qosay & Hassan, Mohammad & Al-Shar'i, Nizar & El-Elimat, Tamam & Almaaytah, Ammar. (2017). Computational and experimental exploration of the structure-activity relationships of flavonoids as potent glyoxalase-I inhibitors. Drug Development Research. 79. 10.1002/ddr.21421.

Ji M, Xu Q, Li X. Dietary methionine restriction in cancer development and antitumor immunity. Trends Endocrinol Metab. 2024 May;35(5):400-412. doi: 10.1016/j.tem.2024.01.009. Epub 2024 Feb 20. PMID: 38383161; PMCID: PMC11096033.

Kusaczuk M, Krętowski R, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyrate-a pan-HDAC inhibitor-suppresses proliferation of glioblastoma LN-229 cell line. Tumour Biol. 2016 Jan;37(1):931-42. doi: 10.1007/s13277-015-3781-8. Epub 2015 Aug 11. PMID: 26260271; PMCID: PMC4841856.

Xie X, Wu Y, Luo Sh, Yang H, Li L, Zhou S, Shen R, Lin H. Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials. Asian Pac J Cancer Prev. 2017 Feb 1;18(2):479-484. doi: 10.22034/APJCP.2017.18.2.479. PMID: 28345833; PMCID: PMC5454746.

This blog post is for informational, educational, and research purposes only. It is based on scientific research but is not medical advice.

×